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EDITORIAL
Urea: Surrogate or toxin?
Patients who develop progressive renal failure retain time average concentration of urea in the plasma of
solutes normally excreted by healthy kidneys. The result- patients on dialysis have been correlated with patient
ing uremic syndrome eventually leads to clinically appar- outcomes in well-designed clinical studies [3, 4].
ent deterioration in biochemical, physiologic and cellular Despite the ubiquity of urea kinetic modeling as a mea-
function. Uremia also results in dysfunction of a wide sure of dialysis therapy, urea has generally been consid-
variety of specific organ systems, most notably neuro- ered to be relatively non-toxic, functioning more as a surro-
logic, cardiovascular, hematologic, immunologic, and en- gate for other unidentified low molecular weight uremic
docrinologic abnormalities [1]. Left unchecked, uremia toxins [5]. The study by Moeslinger et al in this issue of
ultimately results in death from metabolic and cellular Kidney International [6], as well as several other recent
dysfunction. Fortunately, the past four decades in clinical investigations [7] may cause us to rethink this assumption.
medicine have been witness to the development of dra- Moeslinger and colleagues hypothesized that elevated
matic therapeutic interventions to ameliorate the uremic levels of urea, by increasing macrophage proliferation
syndrome, including the widespread use of renal replace- and inhibiting macrophage apoptosis, could contribute to
ment therapies such as dialysis and renal transplantation. the accelerated atherogenesis frequently seen in patients
Almost since the initial recognition of the uremic syn- with renal failure. Using a mouse-derived monocyte/
drome, there has been a search for “the uremic toxin.”
macrophage cell line, the authors demonstrate that high
The search for uremic toxins has been complicated by
concentrations of urea induce macrophage proliferationboth philosophical and technical issues. Philosophically,
via inhibition of inducible nitric oxide synthesis (iNOS).it is doubtful that any single compound is responsible
The critical role of iNOS in mediating urea-induced mac-for inducing most uremic cellular injury; more likely,
rophage proliferation was further demonstrated with ex-injury occurs as a result of cumulative retention of a
periments using both NO scavengers and donors.multitude of compounds. From a technical standpoint, a
Does urea really contribute to uremic toxicity, or is itmyriad of compounds can be identified from both uremic
merely a surrogate for other toxins? The provocativeultrafiltrate and serum using techniques such as high per-
study by Moeslinger and colleagues needs to be interpre-formance liquid chromatography. However, alterations
ted with caution. The concentration of urea required toin electrostatic charge, protein binding, and molecular
induce macrophage proliferation in these experimentsconfiguration as a consequence of uremia may alter chro-
was generally higher than that seen clinically in well-matographic behavior and make identification difficult.
dialyzed patients with renal failure. Caution must alsoFurthermore, in vitro assays that relate retention of sol-
be used in extrapolating the results of in vitro experimen-utes in uremia to actual cellular toxicity have not been
tation with cell lines to biologically complex in vivo com-standardized. Of most importance, the dialytic clearance
characteristics of most putative uremic toxins have not plications. Despite these limitations, the authors of this
been correlated with morbidity and mortality for patients study are to be congratulated for exploring and ex-
with renal failure. tending our understanding of uremic toxicity. Further
The most abundant solute that accumulates as a by- experimentation using other specific assays of cellular
product of protein metabolism is urea. For over two activation and dysfunction may help clarify the role of
decades, quantitation of the dialytic clearance of urea urea in the uremic syndrome.
has been utilized to measure the adequacy and efficacy
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